公开(公告)号：CA2663502A1

公开(公告)日：2008-03-20

申请号：CA2663502

申请日：2007-09-13

Applicant: SCHERING CORP

Inventor： BENNETT CHAD E ,  ASLANIAN ROBERT G ,  PALANI ANANDAN ,  MCKITTRICK BRIAN A ,  HARRIS JOEL M ,  SMITH ELIZABETH M ,  XIAO DONG ,  BURNETT DUANE A ,  VACCARO HENRY M ,  KIM HYUNJIN M ,  KISELGOF EUGENIA Y ,  KNUTSON CHAD E ,  CHAN TIN-YAU

IPC: C07D471/10 ,  A61K31/438 ,  A61P3/00

Abstract: The present invention relates to Azetidinone Derivatives, compositions co mprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelin ation or nonalcoholic fatty liver disease, comprising administering to a pat ient an effective amount of an Azetidinone Derivative.

公开(公告)号：CA2637897A1

公开(公告)日：2007-07-26

申请号：CA2637897

申请日：2007-01-18

Applicant: SCHERING CORP

Inventor： XU RUO ,  JOSIEN HUBERT B ,  CLADER JOHN W ,  DOMALSKI MARTIN S ,  ASBEROM THEODROS ,  PISSARNITSKI DMITRI A ,  BARA THOMAS ,  KNUTSON CHAD E ,  WU WEN-LIAN ,  QIANG LI ,  CAPLEN MARY ANN ,  SASIKUMAR THAVALAKULAMGAR K ,  RAJAGOPALAN MURALI ,  ZHAO ZHIQIANG ,  BURNETT DUANE A ,  SU JING ,  TANG HAIQUN ,  BENNETT CHAD E ,  LI HONGMEI ,  COLE DAVID J ,  MCBRIAR MARK D

IPC: C07D311/22 ,  C07D311/80 ,  C07D311/92 ,  C07D311/94 ,  C07D313/08 ,  C07D335/06

Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

公开(公告)号：CA2619362A1

公开(公告)日：2007-03-01

申请号：CA2619362

申请日：2006-08-16

Applicant: SCHERING CORP

Inventor： BENNETT CHAD E ,  WU WEN-LIAN ,  BURNETT DUANE A

IPC: C07D495/14 ,  A61K31/519 ,  A61P25/00

Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selecti ve metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate recept or (e.g., mGluRI ) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.